Endometriosis New Zealand is welcoming Pharmac’s decision
to publicly fund desogestrel, a move that will significantly
improve access to this important treatment option for people
living with endometriosis.
“This decision
will be a major boost for many New Zealanders affected by
endometriosis,” says Tanya Cooke, Chief Executive of
Endometriosis New Zealand. “For far too long, access to
desogestrel, which is an effective hormonal treatment for
endometriosis, has been dictated by cost rather than
clinical need.”
“Pharmac’s decision is a
vital step towards ensuring that every person with
endometriosis can access desogestrel, regardless of their
financial situation.”
Endometriosis is a chronic and
often debilitating condition that affects around 120,000 New
Zealanders. Desogestrel (known by the brand name Cerazette)
is widely recognised as helping to reduce menstrual bleeding
and associated pain.
“In our advocacy work with
healthcare professionals and the endometriosis community
we’ve repeatedly heard that the lack of funding for
first-line treatments like desogestrel has led to delays in
symptom management,” says Cooke.
“By funding
desogestrel, Pharmac has removed one of the key barriers to
timely, effective treatment of endometriosis and its
often-debilitating symptoms.”
This decision, coming in
the middle of Endometriosis Awareness Month, is a major
boost to those living with endometriosis in New Zealand.
However, there is a long way to go until they receive the
care they deserve, which is why Endometriosis New Zealand
continues to call for a National Endometriosis Action
Plan.
“Ultimately, a National Action Plan for
Endometriosis is required to provide the necessary education
and awareness to primary healthcare professionals, reduce
diagnosis delays and train the specialists Aotearoa needs to
improve care and treatment outcomes for those living with
endometriosis,” says
Cooke.
Advertisement – scroll to continue reading
© Scoop Media



















Discussion about this post